EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes

Kunjal Patel iD, Alicia Jaramillo-Underwood, Brad Karalius, Tzy-Jyun Yao, Russell B Van Dyke, Ayesha Mirza iD, Jennifer Jao iD, Allison L Agwu, Pediatric HIV/AIDS Cohort Study (PHACS)

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Kunjal Patel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV Integrase Inhibitors. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of integrase strand transfer inhibitors (INSTIs) among adults with HIV is well-established, though adverse effects, particularly weight gain, are common. Comparable data for treatment-experienced adolescents and young adults with perinatally-acquired HIV (AYAPHIV) are limited.

Methods

AYAPHIV in the US-based Pediatric HIV/AIDS Cohort Study who switched to bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG), or raltegravir (RAL) from any prior regimen were eligible. Using mixed-effects models, viral load, CD4 count, weight, and body mass index were described through 2 years after switch for each INSTI.

Results

Among 556 AYAPHIV, there were 167 switches to BIC, 282 to DTG, 189 to EVG, and 151 to RAL. Viral suppression (<200 copies/mL) at 1 and 2 years after switch was 74% and 69% for BIC, 62% and 60% for DTG, 76% and 68% for EVG, and 58% and 52% for RAL. Mean CD4 counts were above 500 cells/mm3 after switch through 2 years for all INSTIs. Average weight gain in the first year after switch to BIC, DTG, EVG, and RAL was 0.2, 2.5, 3.8, and −0.2 kilograms for females and 2.3, 4.8, 2.9, and 2.6 kilograms for males. Among previously underweight/healthy individuals, 13%, 18%, 36%, and 12% of females and 6%, 8%, 12%, and 11% of males switching to BIC, DTG, EVG, and RAL were overweight/obese by 2 years after switch.

Conclusions

Individual INSTI-based regimens among treatment-experienced AYAPHIV had moderate effectiveness with respect to viral suppression. Continued average weight gain across INSTIs raises concerns about long-term cardiometabolic sequalae.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV Integrase InhibitorsHumansFemaleMaleViral LoadYoung AdultAdolescentCD4 Lymphocyte CountPyridonesHeterocyclic Compounds, 3-RingRaltegravir PotassiumPiperazinesOxazinesUnited StatesQuinolonesWeight GainTreatment OutcomeAdultCohort StudiesHeterocyclic Compounds, 4 or More RingsBody Mass Index

Stichwörter der Autor:innen

CD4 countHIV viral loadintegrase strand transfer inhibitorsperinatal HIVweight gain

Substanzen

HIV Integrase InhibitorsPyridonesHeterocyclic Compounds, 3-RingelvitegravirRaltegravir PotassiumPiperazinesOxazinesbictegravirQuinolonesHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Department of Pediatrics, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Kunjal Patel, Ayesha Mirza, Jennifer Jao

Förderung

  • NICHD NIH HHS

Zitieren

APA

Patel, K., Jaramillo-Underwood, A., Karalius, B., Yao, T. J., Van Dyke, R. B., Mirza, A., Jao, J., Agwu, A. L., & Pediatric HIV/AIDS Cohort Study (PHACS) (2026). Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf538

Vancouver

Patel K, Jaramillo-Underwood A, Karalius B, Yao TJ, Van Dyke RB, Mirza A, et al. Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf538

BibTeX
@article{Patel2026,
  author = {Patel, Kunjal and Jaramillo-Underwood, Alicia and Karalius, Brad and Yao, Tzy-Jyun and Van Dyke, Russell B and Mirza, Ayesha and Jao, Jennifer and Agwu, Allison L and Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS)},
  title = {Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf538}
}
Kostenlos starten →